Injectable Proteasome Inhibitor Route. Production-scale synthesis of injectable peptide boronic acids derived from (1S,2S,3R,5S)-(+)-2,3-pinanediol is governed by water activity in the esterification reactor. The diol is coupled to an alkylboronic acid at a molar feed of 1.00–1.05 mol per mol boronic acid; an excess of more than 0.05 mol leads to a terpene residue that can survive three crystallizations and exceed the ICH Q3C-based acceptance limit in the parenteral formulation. The esterification is run in anhydrous tetrahydrofuran over activated 3A molecular sieves, with Karl Fischer moisture held below 500 ppm; in this environment, the pinanediol ester acts as a configurational lock during subsequent Matteson homologation with lithium dichloromethanide at −60 °C to −50 °C. Deprotection is performed by biphasic hydrolysis with 2.0 N hydrochloric acid and methyl tert-butyl ether; the aqueous phase is extracted twice, and the combined organic streams are washed with 1.0 M sodium bicarbonate until residual pinanediol is below 0.10% w/w by GC-FID. Injectable-grade API is then lyophilized from a solution containing 20–30 mg/mL mannitol as bulking agent at pH 4.5–5.5; terminal sterile filling follows FDA 21 CFR 211.165, with no terminal sterilization because the boronic acid peptide is thermolabile. Batch release includes ICH Q7 GMP review, ICH Q3C residual solvent control for tetrahydrofuran and methyl tert-butyl ether, ICH Q3D elemental impurity testing for palladium and nickel, and USP <788> particulate matter for injectable solutions. The terminal product is a white lyophilized cake or powder for intravenous or subcutaneous administration after reconstitution with normal saline.

What Changes When the Pinanediol Ester Route Feeds an Oral Capsule Line Instead of an Injectable Line?

For oral capsule manufacture, the pinanediol-derived intermediate is converted to a free boronic acid and then salified with citric acid to produce a solid, non-hygroscopic citrate salt. The pinanediol ester is hydrolyzed under acidic conditions that differ from the injectable route: a cooled 1.5 N hydrochloric acid solution at 0–5 °C is used, and the resulting boronic acid is extracted into ethyl acetate before salification in isopropanol. Molar ratios in the salification step are specified at 1.00–1.05 mol of citric acid per mol of boronic acid to avoid residual free acid that would reduce capsule content uniformity. After isolation, the API is milled and passed through a 60-mesh screen so that d50 is below 75 µm. The formulation is a dry blend of API, lactose monohydrate, microcrystalline cellulose, and crospovidone; this blend is granulated with a 5–8% w/w aqueous povidone K30 solution in a fluid-bed granulator at inlet air temperature 55–65 °C. Granule moisture is controlled below 2.0% by Karl Fischer titration, because water above this threshold hydrolyzes the boronic acid in the solid state and causes impurity formation during stability. The granules are lubricated with 0.5–1.0% w/w sodium stearyl fumarate and filled into size 3 HPMC capsules; weight variation follows USP <905> and dissolution acceptance uses USP <711> in 0.1 N HCl. Compliance for this route includes ICH Q7 for GMP, ICH Q3C for residual ethyl acetate and isopropanol, ICH Q3D for palladium and zinc from upstream reductions, and the relevant capsule general chapters for microbial limits. The terminal dosage form is an immediate-release oral capsule containing a boronic acid proteasome inhibitor.

Chiral Allylboration Scope in N-Protected Amino Aldehyde Routes for Antiviral Tablet Intermediates

Pinanediol allyl boronate reagents derived from (1S,2S,3R,5S)-(+)-2,3-pinanediol add to N-Boc amino aldehydes to generate chiral homoallylic alcohols with defined anti/syn ratios. The cryogenic addition is run in anhydrous dichloromethane or toluene at −70 °C to −60 °C under nitrogen; the aldehyde is added as a 0.5–1.0 M solution over 1–2 h to maintain a local boronate excess of 1.2–1.5 equivalents. Enantioselectivity is monitored by chiral HPLC, and batches showing less than 92% enantiomeric excess are rejected before oxidative workup. Workup is performed with 2.0 M sodium acetate buffer at pH 8.5 and 30% hydrogen peroxide at 0–5 °C; the resulting 1,2-amino alcohol is extracted into ethyl acetate and distilled under vacuum at 40–50 °C jacket temperature. The tablet-grade API obtained after subsequent deprotection and salt formation is crystalline and is formulated by dry granulation with pregelatinized starch, croscarmellose sodium, and microcrystalline cellulose. Residual solvent limits are set according to ICH Q3C; specifically, toluene is controlled below 890 ppm and dichloromethane below 600 ppm in the API, as per USP <467> procedure for residual solvents. The final tablet core is compressed to hardness 8–12 kp and coated with an aqueous film coat; disintegration is tested by USP <701> and dissolution by USP <711>. The terminal product is a film-coated tablet containing an antiviral protease or polymerase inhibitor whose chiral amino alcohol motif originated from the pinanediol-controlled allylation step.

Cardiovascular Tablet API Isolation via Diastereomeric Boronate Crystallization. Cardiovascular tablet API isolation via diastereomeric boronate crystallization uses (1S,2S,3R,5S)-(+)-2,3-pinanediol as a recoverable chiral handle. A racemic α-chloro boronic ester intermediate is prepared from the diol and racemic substrate in a 1.0–1.1:1.0 molar ratio; the two diastereomers are separated by slurry crystallization from n-heptane/ethyl acetate 6:1 at −10 °C to −5 °C. The desired diastereomer is collected with 98–99% diastereomeric excess after two slurries, and the mother liquor is recycled to recover the undesired enantiomer after epimerization at the chlorine center. Hydrolysis of the resolved ester with 3.0 N acetic acid in tetrahydrofuran at 20–25 °C releases the chiral α-chloro boronic acid; the pinanediol is recovered from the organic phase by distillation at 90–100 °C under reduced pressure for reuse. Tablet manufacturing of the final hydrochloride salt uses direct compression: 10–15% w/w active ingredient, 55–65% w/w microcrystalline cellulose, 20–30% w/w lactose monohydrate, 3–5% w/w crospovidone, and 1.0% w/w magnesium stearate. The powder blend is compressed at 12–18 kN on a rotary tablet press to 200 mg tablet cores; hardness is maintained at 8–12 kp, and friability is below 0.5% by USP <1216>. Published data for this specific configuration is limited; the ranges are derived from pilot-scale batches and should be verified against site-specific API particle size and flow behavior. Compliance for this route includes ICH Q7, ICH Q3C for n-heptane and ethyl acetate, ICH Q3D for residual boron and metal catalysts, and FDA 21 CFR 211.165 for release testing. The terminal product is an immediate-release tablet for hypertension or heart failure; the residual pinanediol is controlled below 0.05 ppm in the final API released for tableting.

When Oral Granule Dosage Forms Require Low Terpene Residues to Avoid Gastrointestinal Irritation

Oral granule formulations of APIs produced via pinanediol chiral intermediates require stricter residual terpene control than tablet or capsule intermediates because granules may be taken by pediatric patients and are often dispersed in water before administration. The pinanediol-derived API is purified by repeated slurry in n-heptane/ethyl acetate 4:1 at 0–5 °C; each slurry cycle reduces residual pinanediol by approximately one log unit, so three cycles are required to bring the content from 0.5% w/w to below 0.0005% w/w. The granule formulation is produced by top-spray fluid-bed granulation using a binder solution of 3–7% w/w povidone K30 in purified water; the API is preblended with mannitol and xylitol in a 1:2:1 ratio to mask bitterness and to provide a rapidly dispersing matrix. Inlet air temperature is maintained at 50–60 °C, while product temperature remains below 35 °C to preserve the amorphous fraction of the API at the target granule moisture of 1.5–2.0%. Dried granules pass through a 20-mesh screen and are filled into single-dose sachets at target fill weight 1.00 g ± 5.0%; each sachet contains 10–50 mg active moiety. Compliance includes ICH Q7 for the API, ICH Q3C for residual n-heptane and ethyl acetate, ICH Q3D for residual palladium and zinc, and the relevant general chapters for uniformity of dosage units. The terminal product is a dispersible granule in unit-dose sachets, intended for suspension in water for oral administration.

Lyophilized Injectable β-Lactamase Inhibitor Combination Products Requiring Low Endotoxin Input from Pinanediol Intermediates

β-Lactamase inhibitor APIs containing a cyclic boronic acid core can be assembled using pinanediol as a temporary dioxaborolane protecting group; this route is distinct from peptide boronate chemistry because the final API is paired with a cephalosporin or carbapenem in a sterile fixed-dose combination. The pinanediol ester is generated in a 1.00–1.10 molar ratio with the boronic acid precursor in anhydrous 2-methyltetrahydrofuran; water is held below 300 ppm because the cyclic ester is more hydrolytically labile than the peptide boronate intermediates. Deprotection is carried out in a two-phase system of 2.0 N HCl and methyl tert-butyl ether at 0–5 °C; the aqueous layer is repeatedly extracted until the pinanediol concentration is below 0.10% w/w by gas chromatography. The final API is lyophilized with the antibiotic component at pH 5.0–6.0; the cycle includes a −40 °C freezing hold and a primary drying shelf temperature of −20 °C to −10 °C to prevent collapse. Sterile filtration occurs through a 0.2 µm polyethersulfone membrane, and the sterile bulk is filled into 10 mL glass vials under ISO 14644-1 Class 5 conditions. Release testing includes ICH Q3C for 2-methyltetrahydrofuran and methyl tert-butyl ether, ICH Q3D for boron and palladium, bacterial endotoxin testing per USP <85>, and particulate matter per USP <788>. The terminal product is a sterile lyophilized powder for intravenous infusion in a combination antibiotic regimen.